Improving Your Cell-Based Research with Real-Time Assays

With traditional cell-based endpoint assays you can miss important cellular events if measurement isn't taken at the appropriate time, particularly when characterizing a compound's effect on cells. Additionally, assay reagents can negatively affect cell health and endpoint assays can impede downstream multiplexing.

View Webinar Recording Link

Terry Riss, PhD
Global Strategic Marketing Manager, Cell Health

Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 and held several R&D and Project Management positions since. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also lead efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death.  Dr. Riss now serves as Global Strategic Marketing Manager, Cell Health involved in outreach educational training activities.